NASDAQ : CSCI

COSCIENS Biopharma Inc.

$2.72 USD

$0 (0.0%)

Volume
0
Average Volume
9.72K
Market Capitalization
$8.57M
P/E Ratio
-0.37
Dividend Yield
0.00%
Price Target
Year High
$4.61
Year Low
$1.75
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.57
Company Overview

NASDAQ

Anna Elizabeth Biehn

Biotechnology

Healthcare

CSCI

40

CA

USD

https://www.cosciensbio.com

908-824-0775

22112H101

0001113423

Liquidity Metrics

0.13

5.57

4.92

2.97

0.00

Sales & Valuation

$13.78M

0.76

0.13

-0.68

-25.20

Profitability

-$5.93

-$15.31M

-92.11%

-87.57%

-92.88%

-38.59%

P/E Metrics

-0.37

-0.02

-0.02

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

-1.82

3/9

$10.97M

$27.56M

$20.46M

-$17.72M

Key Metrics (TTM)

$2.82M

0.36

-0.44

5.57

-92.88%

-43.69%

-381.24%

-151.55%

130 days

Company Executives
Name Title
Matthias Gerlach Senior Vice President Manufacturing and Supply Chain & Head of Production
Michael Teifel Senior Vice President of GmbH & Chief Scientific Officer
Michel Regnier Senior Vice President of Technical operations, MD of Ceapro Inc. & Chief Technology Officer
Anna Elizabeth Biehn Chief Executive Officer
Gilles R. Gagnon President, Chief Executive Officer & Director
Giuliano La Fratta Senior Vice President of Finance & Chief Financial Officer
Nicola Ammer Chief Medical Officer & Senior Vice President of Clinical Development
Poll Results

No votes yet today — be the first to share your view!

About COSCIENS Biopharma Inc. (NASDAQ:CSCI) Stock

COSCIENS Biopharma Inc. is a specialized biopharmaceutical company dedicated to the global development and commercialization of innovative therapeutic and diagnostic products. Its operations extend across Canada, Switzerland, Ireland, Denmark, Germany, the United States, and other international territories. The company's flagship product is Macrilen (macimorelin), an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound works by stimulating growth hormone secretion through its interaction with the GHSR-1a receptor, primarily serving for the diagnosis of both adult and childhood-onset growth hormone deficiency. It also shows promise in other endocrinology and oncology applications. Its pipeline includes AEZS-150, a delayed-clearance parathyroid hormone fusion ... polypeptide currently undergoing preclinical evaluation for the management of chronic hypoparathyroidism. Another preclinical candidate, AEZS-130, is being investigated for its potential in treating amyotrophic lateral sclerosis (ALS). COSCIENS has established a license and research collaboration with the University of Wuerzburg. This partnership aims to develop, produce, and market AIM biologicals targeting neuromyelitis optica spectrum disorder, alongside conducting preclinical research into their potential for Parkinson's disease treatment. To further its commercial efforts for Macrilen, the company has licensing agreements with Consilient Health Ltd. and NK MEDITECH Ltd. for its development and commercialization, as well as a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood specifically for Macrilen's diagnostic application in pediatric and adult growth hormone deficiency. Further collaborations include an agreement with The University of Sheffield in the United Kingdom, focused on the development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to address chronic hypoparathyroidism. Originally incorporated in 1990 as Aeterna Zentaris Inc., the company officially rebranded as COSCIENS Biopharma Inc. in August 2024. Its corporate headquarters are located in Toronto, Canada.

COSCIENS Biopharma Inc. Reports Q2 2026 Results

2026-08-11 17:30:00

TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“COSCIENS” or the “Company”) today reported its financial and operating results for the second quarter ended June 30, 2026. All amounts in this press release are in U.S. dollars.

COSCIENS Biopharma Inc. Completes Share Capital Amendment

2026-07-03 08:30:00

TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), today announced the previously announced consolidation (the “Consolidation”) of the common shares of the Company (the “Common Shares”) on the basis of a ratio of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the “Consolidation Ratio”); and (ii) an immediate subsequent split (the “Split”) of the Common Shares on the basis of 50 Common Shares for every one post-Consolidation Common Share (collectively, the “Share Capital Amendment”), became effective today (the “Effective Date”).

COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment

2026-06-22 20:16:00

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company's share capital (the “Share Capital Amendment”).

COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO

2026-06-18 08:30:00

TORONTO, ONTARIO, June 18, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the results from its annual general and special meeting of shareholders (the “Meeting”). At the Meeting, all matters put to shareholders for consideration and approval, as set out in the Company's management proxy circular dated May 18, 2026 (the “Circular”), were approved by the requisite number of votes cast at the Meeting, including (1) the re-election of all director nominees, (2) the re-appointment of Deloitte LLP as auditors, and (3) the authorization to proceed with the changes in the Company's share capital the (“Share Capital Amendment”), consisting of (i) the consolidation (the “Consolidation”) of the Company's common shares (“Common Shares”) on the basis of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the “Consolidation Ratio”); and (ii) the immediate subsequent split (the “Split”) of the Common Shares on the basis of 50 Common Shares for every one post-Consolidation Common Share.

CSCI Leverages Technology, Workforce Expansion, and Operational Discipline to Drive Continued Growth Across Florida

2026-06-11 08:17:00

BOYNTON BEACH, Fla.--(BUSINESS WIRE)-- #BuildingFlorida--CSCI drives continued Florida growth through expanded market share, technology innovation, workforce expansion, and record housing starts.

COSCIENS Biopharma Inc. Reports Q1 2026 Results

2026-05-12 17:05:00

TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the first quarter ended March 31, 2026. All amounts in this press release are in U.S. dollars.

Frequently Asked Questions

What is the current COSCIENS Biopharma Inc. (CSCI) stock price?

COSCIENS Biopharma Inc.(NASDAQ:CSCI) stock price is $2.72 in the last trading session. During the trading session, CSCI stock reached the peak price of $4.6054 while $1.75 was the lowest point it dropped to. The percentage change in CSCI stock occurred in the recent session was 0.0% while the dollar amount for the price change in CSCI stock was $0.

CSCI's industry and sector of operation?

The NASDAQ listed CSCI is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CSCI?

Matthias Gerlach | Senior Vice President Manufacturing and Supply Chain & Head of Production
Michael Teifel | Senior Vice President of GmbH & Chief Scientific Officer
Michel Regnier | Senior Vice President of Technical operations, MD of Ceapro Inc. & Chief Technology Officer
Anna Elizabeth Biehn | Chief Executive Officer
Gilles R. Gagnon | President, Chief Executive Officer & Director

How many employees does CSCI have?

Number of CSCI employees currently stands at 40. CSCI operates from 222 Bay Street, Toronto, ON M5K 1E7, CA.

Link for CSCI official website?

Official Website of CSCI is: https://www.cosciensbio.com

How do I contact CSCI?

CSCI could be contacted at phone #908-824-0775 and can also be accessed through its website. CSCI operates from 222 Bay Street, Toronto, ON M5K 1E7, CA.

How many shares of CSCI are traded daily?

The average number of CSCI shares traded daily for last 3 months was 9.72K.

What is the market cap of CSCI currently?

The market value of CSCI currently stands at $8.57M with its latest stock price at $2.72